CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma.
Tingdang LiuXiming DaiYien XuTian GuanLiangli HongTahir ZaibQi ZhouKe ChengXiaoling ZhouChangchun MaPingnan SunPublished in: Journal of translational medicine (2023)
CD22 is a potential tumor surface antigen capable of being targeted by CAR-NK cells in ESCC. And potential therapeutics for ESCC may be developed based on immune cells expressing anti-CD22 CAR. The study also indicates that CD22 CAR-NK cells could be used in other cancers and more in vivo experiments are needed.